Further observations on the unique efficacy of picoTesla range magnetic fields in Parkinson's disease.
External application of picoTesla range magnetic fields (MF) has been reported recently to be efficacious in the treatment of patients with Parkinson's disease (PD) including those who manifest levodopa-related dyskinesias. In the present communication, we present four additional Parkinsonian patients who showed, within a brief period of time, marked improvement in motor symptoms after therapy with MF. Three of the patients had been maintained on antiParkinsonian medication during treatment with MF while the fourth patient had never received pharmacotherapy. Improvement with magnetic therapy was noted not only in the motor sphere (resting tremor, gait apraxia, postural instability), but also in nonmotor aspects of the disease including mood, sleep, pain, anorexia, autonomic, and cognitive functions attesting to the unique efficacy of external picoTesla range MF in the treatment of Parkinsonism. Poverty of facial expression (hypomimia, "masked facies"), which correlates with the degree of striatal dopaminergic deficiency, is one of the clinical hallmarks of PD reflecting the severity of hypokinesia and rigidity in the orofacial musculature. In this report, we emphasize the effects of MF on the hypomimia of PD and provide visual documentation illustrating the changes in the patients' facial expression which follow treatment with MF.
Sandyk
R
R
NeuroCommunication Research Laboratories, Danbury, CT 06811.
Derpapas
K
K
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D004574:Electromagnetic Fields; D005149:Facial Expression; D005260:Female; D006801:Humans; D008297:Male; D008550:Melatonin / Q000378:metabolism; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000628:therapy*; D010870:Pineal Gland; D011187:Posture; D012701:Serotonin; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D012701:Serotonin; D008550:Melatonin